Browse > Article
http://dx.doi.org/10.14348/molcells.2021.0032

The Role of Gut Microbiota in Modulating Tumor Growth and Anticancer Agent Efficacy  

Kim, Jaeho (Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST))
Lee, Heung Kyu (Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST))
Publication Information
Molecules and Cells / v.44, no.5, 2021 , pp. 356-362 More about this Journal
Abstract
An increasing number of studies have revealed an interaction between gut microbiota and tumors. The enrichment of specific bacteria strains in the intestines has been found to modulate tumor growth and influence the mechanisms of tumor treatment. Various bacteria are involved in modulating the effects of chemotherapeutic drugs currently used to treat patients with cancer, and they affect not only gastrointestinal tract tumors but also distant organ tumors. In addition, changes in the gut microbiota are known to be involved in the antitumor immune response as well as the modulation of the intestinal immune system. As a result, the gut microbiota plays an important role in modulating the efficacy of immune checkpoint inhibitors. Therefore, gut microbiota could be considered as an adjuvant treatment option with other cancer treatment or as another marker for predicting treatment response. In this review, we examine how gut microbiota affects cancer treatments.
Keywords
cancer; cancer therapy; gut microbiota; immune checkpoint inhibitors;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Sivan, A., Corrales, L., Hubert, N., Williams, J.B., Aquino-Michaels, K., Earley, Z.M., Benyamin, F.W., Lei, Y.M., Jabri, B., Alegre, M.L., et al. (2015). Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 350, 1084-1089.   DOI
2 Shin, J.M., Luo, T., Kamarajan, P., Fenno, J.C., Rickard, A.H., and Kapila, Y.L. (2017). Microbial communities associated with primary and metastatic head and neck squamous cell carcinoma - a high fusobacterial and low streptococcal signature. Sci. Rep. 7, 9934.   DOI
3 Shui, L., Yang, X., Li, J., Yi, C., Sun, Q., and Zhu, H. (2019). Gut microbiome as a potential factor for modulating resistance to cancer immunotherapy. Front. Immunol. 10, 2989.   DOI
4 Takagi, A., Ikemura, H., Matsuzaki, T., Sato, M., Nomoto, K., Morotomi, M., and Yokokura, T. (2008). Relationship between the in vitro response of dendritic cells to Lactobacillus and prevention of tumorigenesis in the mouse. J. Gastroenterol. 43, 661-669.   DOI
5 Tanoue, T., Morita, S., Plichta, D.R., Skelly, A.N., Suda, W., Sugiura, Y., Narushima, S., Vlamakis, H., Motoo, I., Sugita, K., et al. (2019). A defined commensal consortium elicits CD8 T cells and anti-cancer immunity. Nature 565, 600-605.   DOI
6 Davar, D., Dzutsev, A.K., McCulloch, J.A., Rodrigues, R.R., Chauvin, J.M., Morrison, R.M., Deblasio, R.N., Menna, C., Ding, Q., Pagliano, O., et al. (2021). Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science 371, 595-602.   DOI
7 Jandhyala, S.M., Talukdar, R., Subramanyam, C., Vuyyuru, H., Sasikala, M., and Nageshwar Reddy, D. (2015). Role of the normal gut microbiota. World J. Gastroenterol. 21, 8787-8803.   DOI
8 GBD 2015 Disease and Injury Incidence and Prevalence Collaborators (2016). Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388, 1545-1602.   DOI
9 Kim, C.H., Park, J., and Kim, M. (2014). Gut microbiota-derived short-chain Fatty acids, T cells, and inflammation. Immune Netw. 14, 277-288.   DOI
10 Kodawara, T., Higashi, T., Negoro, Y., Kamitani, Y., Igarashi, T., Watanabe, K., Tsukamoto, H., Yano, R., Masada, M., Iwasaki, H.J.B., et al. (2016). The inhibitory effect of ciprofloxacin on the β-glucuronidase-mediated deconjugation of the irinotecan metabolite SN-38-G. Basic Clin. Pharmacol. Toxicol. 118, 333-337.   DOI
11 Yu, A.I., Zhao, L., Eaton, K.A., Ho, S., Chen, J., Poe, S., Becker, J., Gonzalez, A., McKinstry, D., Hasso, M., et al. (2020). Gut microbiota modulate CD8 T cell responses to influence colitis-associated tumorigenesis. Cell Rep. 31, 107471.   DOI
12 Zitvogel, L., Galluzzi, L., Viaud, S., Vetizou, M., Daillere, R., Merad, M., and Kroemer, G. (2015). Cancer and the gut microbiota: an unexpected link. Sci. Transl. Med. 7, 271ps1.
13 Jung, J., Surh, C.D., and Lee, Y.J. (2019). Microbial colonization at early life promotes the development of diet-induced CD8αβ intraepithelial T cells. Mol. Cells 42, 313-320.   DOI
14 Long, X., Wong, C.C., Tong, L., Chu, E.S.H., Ho Szeto, C., Go, M.Y.Y., Coker, O.O., Chan, A.W.H., Chan, F.K.L., Sung, J.J.Y., et al. (2019). Peptostreptococcus anaerobius promotes colorectal carcinogenesis and modulates tumour immunity. Nat. Microbiol. 4, 2319-2330.   DOI
15 Uribe-Herranz, M., Rafail, S., Beghi, S., Gil-de-Gomez, L., Verginadis, I., Bittinger, K., Pustylnikov, S., Pierini, S., Perales-Linares, R., Blair, I.A., et al. (2020). Gut microbiota modulate dendritic cell antigen presentation and radiotherapy-induced antitumor immune response. J. Clin. Invest. 130, 466-479.   DOI
16 Vetizou, M., Pitt, J.M., Daillere, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M.P., Duong, C.P., et al. (2015). Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 350, 1079-1084.   DOI
17 Waldmann, T.A. (2003). Immunotherapy: past, present and future. Nat. Med. 9, 269-277.   DOI
18 Konishi, H., Fujiya, M., Tanaka, H., Ueno, N., Moriichi, K., Sasajima, J., Ikuta, K., Akutsu, H., Tanabe, H., and Kohgo, Y. (2016). Probiotic-derived ferrichrome inhibits colon cancer progression via JNK-mediated apoptosis. Nat. Commun. 7, 12365.   DOI
19 Ku, K., Park, I., Kim, D., Kim, J., Jang, S., Choi, M., Choe, H.K., and Kim, K. (2020). Gut microbial metabolites induce changes in circadian oscillation of clock gene expression in the mouse embryonic fibroblasts. Mol. Cells 43, 276-285.   DOI
20 Viaud, S., Saccheri, F., Mignot, G., Yamazaki, T., Daillere, R., Hannani, D., Enot, D.P., Pfirschke, C., Engblom, C., Pittet, M.J., et al. (2013). The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 342, 971-976.   DOI
21 Louis, P., Hold, G.L., and Flint, H.J. (2014). The gut microbiota, bacterial metabolites and colorectal cancer. Nat. Rev. Microbiol. 12, 661-672.   DOI
22 Kuen, D.S., Kim, B.S., and Chung, Y. (2020). IL-17-producing cells in tumor immunity: friends or foes? Immune Netw. 20, e6.   DOI
23 Laborda-Illanes, A., Sanchez-Alcoholado, L., Dominguez-Recio, M.E., Jimenez-Rodriguez, B., Lavado, R., Comino-Mendez, I., Alba, E., and Queipo-Ortuno, M.I. (2020). Breast and gut microbiota action mechanisms in breast cancer pathogenesis and treatment. Cancers (Basel) 12, 2465.   DOI
24 Lehouritis, P., Cummins, J., Stanton, M., Murphy, C.T., McCarthy, F.O., Reid, G., Urbaniak, C., Byrne, W.L., and Tangney, M. (2015). Local bacteria affect the efficacy of chemotherapeutic drugs. Sci. Rep. 5, 14554.   DOI
25 Miller, K.D., Nogueira, L., Mariotto, A.B., Rowland, J.H., Yabroff, K.R., Alfano, C.M., Jemal, A., Kramer, J.L., and Siegel, R.L. (2019). Cancer treatment and survivorship statistics, 2019. CA Cancer J. Clin. 69, 363-385.   DOI
26 Scott, T.A., Quintaneiro, L.M., Norvaisas, P., Lui, P.P., Wilson, M.P., Leung, K.Y., Herrera-Dominguez, L., Sudiwala, S., Pessia, A., Clayton, P.T., et al. (2017). Host-microbe co-metabolism dictates cancer drug efficacy in C. elegans. Cell 169, 442-456.e18.   DOI
27 Nevala-Plagemann, C., Hidalgo, M., and Garrido-Laguna, I. (2020). From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer. Nat. Rev. Clin. Oncol. 17, 108-123.   DOI
28 Selwyn, F.P., Cui, J.Y., and Klaassen, C.D. (2015). RNA-Seq quantification of hepatic drug processing genes in germ-free mice. Drug Metab. Dispos. 43, 1572-1580.   DOI
29 Tomasetti, C. and Vogelstein, B. (2015). Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisions. Science 347, 78-81.   DOI
30 Matson, V., Fessler, J., Bao, R., Chongsuwat, T., Zha, Y., Alegre, M.L., Luke, J.J., and Gajewski, T.F.J.S. (2018). The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science 359, 104-108.   DOI
31 Pflug, N., Kluth, S., Vehreschild, J.J., Bahlo, J., Tacke, D., Biehl, L., Eichhorst, B., Fischer, K., Cramer, P., Fink, A.M., et al. (2016). Efficacy of antineoplastic treatment is associated with the use of antibiotics that modulate intestinal microbiota. Oncoimmunology 5, e1150399.   DOI
32 Routy, B., Le Chatelier, E., Derosa, L., Duong, C.P.M., Alou, M.T., Daillere, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M.P., et al. (2018). Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359, 91-97.   DOI
33 Sekirov, I., Russell, S.L., Antunes, L.C., and Finlay, B.B. (2010). Gut microbiota in health and disease. Physiol. Rev. 90, 859-904.   DOI
34 Sender, R., Fuchs, S., and Milo, R. (2016). Revised estimates for the number of human and bacteria cells in the body. PLoS Biol. 14, e1002533.   DOI
35 Sethi, V., Kurtom, S., Tarique, M., Lavania, S., Malchiodi, Z., Hellmund, L., Zhang, L., Sharma, U., Giri, B., Garg, B., et al. (2018). Gut microbiota promotes tumor growth in mice by modulating immune response. Gastroenterology 155, 33-37.e6.   DOI
36 Panek, M., Cipcic Paljetak, H., Baresic, A., Peric, M., Matijasic, M., Lojkic, I., Vranesic Bender, D., Krznaric, Z., and Verbanac, D. (2018). Methodology challenges in studying human gut microbiota - effects of collection, storage, DNA extraction and next generation sequencing technologies. Sci. Rep. 8, 5143.   DOI
37 Roy, S. and Trinchieri, G. (2017). Microbiota: a key orchestrator of cancer therapy. Nat. Rev. Cancer 17, 271-285.   DOI
38 Rubinstein, M.R., Wang, X., Liu, W., Hao, Y., Cai, G., and Han, Y.W. (2013). Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. Cell Host Microbe 14, 195-206.   DOI
39 Yamamura, K., Baba, Y., Nakagawa, S., Mima, K., Miyake, K., Nakamura, K., Sawayama, H., Kinoshita, K., Ishimoto, T., Iwatsuki, M., et al. (2016). Human microbiome Fusobacterium nucleatum in esophageal cancer tissue is associated with prognosis. Clin. Cancer Res. 22, 5574-5581.   DOI
40 Xu, C., Ruan, B., Jiang, Y., Xue, T., Wang, Z., Lu, H., Wei, M., Wang, S., Ye, Z., Zhai, D.J.B., et al. (2017). Antibiotics-induced gut microbiota dysbiosis promotes tumor initiation via affecting APC-Th1 development in mice. Biochem. Biophys. Res. Commun. 488, 418-424.   DOI
41 Yu, T., Guo, F., Yu, Y., Sun, T., Ma, D., Han, J., Qian, Y., Kryczek, I., Sun, D., Nagarsheth, N., et al. (2017). Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy. Cell 170, 548-563.e16.   DOI
42 Yuan, L., Zhang, S., Li, H., Yang, F., Mushtaq, N., Ullah, S., Shi, Y., An, C., and Xu, J. (2018). The influence of gut microbiota dysbiosis to the efficacy of 5-Fluorouracil treatment on colorectal cancer. Biomed. Pharmacother. 108, 184-193.   DOI
43 Zhu, Q., Gao, R., Wu, W., and Qin, H. (2013). The role of gut microbiota in the pathogenesis of colorectal cancer. Tumour Biol. 34, 1285-1300.   DOI
44 Daillere, R., Vetizou, M., Waldschmitt, N., Yamazaki, T., Isnard, C., PoirierColame, V., Duong, C.P.M., Flament, C., Lepage, P., Roberti, M.P., et al. (2016). Enterococcus hirae and Barnesiella intestinihominis facilitate cyclophosphamide-induced therapeutic immunomodulatory effects. Immunity 45, 931-943.   DOI
45 Baruch, E.N., Youngster, I., Ben-Betzalel, G., Ortenberg, R., Lahat, A., Katz, L., Adler, K., Dick-Necula, D., Raskin, S., Bloch, N., et al. (2021). Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science 371, 602-609.   DOI
46 Choi, J. and Lee, S.Y. (2020). Clinical characteristics and treatment of immune-related adverse events of immune checkpoint inhibitors. Immune Netw. 20, e9.   DOI
47 Coleman, R.L., Monk, B.J., Sood, A.K., and Herzog, T.J. (2013). Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat. Rev. Clin. Oncol. 10, 211-224.   DOI
48 Finlay, B.B., Goldszmid, R., Honda, K., Trinchieri, G., Wargo, J., and Zitvogel, L.J.N.R.I. (2020). Can we harness the microbiota to enhance the efficacy of cancer immunotherapy? Nat. Rev. Immunol. 20, 522-528.   DOI
49 Gaiser, R.A., Halimi, A., Alkharaan, H., Lu, L., Davanian, H., Healy, K., Hugerth, L.W., Ateeb, Z., Valente, R., Fernandez Moro, C., et al. (2019). Enrichment of oral microbiota in early cystic precursors to invasive pancreatic cancer. Gut 68, 2186-2194.   DOI
50 Garcia-Gonzalez, A.P., Ritter, A.D., Shrestha, S., Andersen, E.C., Yilmaz, L.S., and Walhout, A.J.M. (2017). Bacterial metabolism affects the C. elegans response to cancer chemotherapeutics. Cell 169, 431-441.e8.   DOI
51 Alexander, J.L., Wilson, I.D., Teare, J., Marchesi, J.R., Nicholson, J.K., and Kinross, J.M. (2017). Gut microbiota modulation of chemotherapy efficacy and toxicity. Nat. Rev. Gastroenterol. Hepatol. 14, 356-365.   DOI
52 Wu, S., Rhee, K.J., Zhang, M., Franco, A., and Sears, C.L. (2007). Bacteroides fragilis toxin stimulates intestinal epithelial cell shedding and gamma-secretase-dependent E-cadherin cleavage. J. Cell Sci. 120(Pt 11), 1944-1952.   DOI
53 Wallace, B.D., Wang, H., Lane, K.T., Scott, J.E., Orans, J., Koo, J.S., Venkatesh, M., Jobin, C., Yeh, L.A., Mani, S., et al. (2010). Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science 330, 831-835.   DOI
54 Wang, T., Cai, G., Qiu, Y., Fei, N., Zhang, M., Pang, X., Jia, W., Cai, S., and Zhao, L. (2012). Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers. ISME J. 6, 320-329.   DOI
55 Wong, S.H., Kwong, T.N.Y., Wu, C.Y., and Yu, J. (2019). Clinical applications of gut microbiota in cancer biology. Semin. Cancer Biol. 55, 28-36.   DOI
56 Iida, N., Dzutsev, A., Stewart, C.A., Smith, L., Bouladoux, N., Weingarten, R.A., Molina, D.A., Salcedo, R., Back, T., Cramer, S., et al. (2013). Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 342, 967-970.   DOI
57 Lee, S.H., Cho, S.Y., Yoon, Y., Park, C., Sohn, J., Jeong, J.J., Jeon, B.N., Jang, M., An, C., Lee, S., et al. (2021). Bifidobacterium bifidum strains synergize with immune checkpoint inhibitors to reduce tumour burden in mice. Nat. Microbiol. 6, 277-288.   DOI
58 Hashim, D., Boffetta, P., La Vecchia, C., Rota, M., Bertuccio, P., Malvezzi, M., and Negri, E. (2016). The global decrease in cancer mortality: trends and disparities. Ann. Oncol. 27, 926-933.   DOI
59 Geller, L.T., Barzily-Rokni, M., Danino, T., Jonas, O.H., Shental, N., Nejman, D., Gavert, N., Zwang, Y., Cooper, Z.A., Shee, K., et al. (2017). Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science 357, 1156-1160.   DOI
60 Gopalakrishnan, V., Spencer, C.N., Nezi, L., Reuben, A., Andrews, M.C., Karpinets, T.V., Prieto, P.A., Vicente, D., Hoffman, K., Wei, S.C., et al. (2018). Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359, 97-103.   DOI
61 Hsieh, Y.Y., Tung, S.Y., Pan, H.Y., Yen, C.W., Xu, H.W., Lin, Y.J., Deng, Y.F., Hsu, W.T., Wu, C.S., and Li, C. (2018). Increased abundance of Clostridium and Fusobacterium in gastric microbiota of patients with gastric cancer in Taiwan. Sci. Rep. 8, 158.   DOI
62 Iizumi, T., Battaglia, T., Ruiz, V., and Perez Perez, G.I. (2017). Gut microbiome and antibiotics. Arch. Med. Res. 48, 727-734.   DOI
63 Jacouton, E., Michel, M.L., Torres-Maravilla, E., Chain, F., Langella, P., and Bermudez-Humaran, L.G. (2018). Elucidating the immune-related mechanisms by which probiotic strain Lactobacillus casei BL23 displays anti-tumoral properties. Front. Microbiol. 9, 3281.   DOI
64 Jan, G., Belzacq, A.S., Haouzi, D., Rouault, A., Metivier, D., Kroemer, G., and Brenner, C. (2002). Propionibacteria induce apoptosis of colorectal carcinoma cells via short-chain fatty acids acting on mitochondria. Cell Death Differ. 9, 179-188.   DOI
65 Ji, B. and Nielsen, J. (2015). From next-generation sequencing to systematic modeling of the gut microbiome. Front. Genet. 6, 219.